Toward Paclitaxel-[60]fullerene immunoconjugates as a targeted prodrug against cancer

Two newly synthesized water-soluble conjugates of Paclitaxel with malonodiserinolamide-derivatized [60]fullerene (C$_{60}$-ser) undergo hydrolysis and release their medical payload under biological conditions. In vivo testing of one of these compounds in a murine model showed tumor volume reduction similar to the FDA-approved drug Abraxane, but without the associated weight-loss, indicating better tolerance of this new formulation.